2488 related articles for article (PubMed ID: 21605862)
1. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
[TBL] [Abstract][Full Text] [Related]
2. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL.
Fujihara Y; Nakamura T; Horikoshi T; Obata JE; Fujioka D; Watanabe Y; Watanabe K; Kugiyama K
Circ J; 2019 May; 83(6):1302-1308. PubMed ID: 30996151
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases.
Nakajima K; Nakajima Y; Takeichi S; Fujita MQ
Atherosclerosis; 2008 May; 198(1):237-46. PubMed ID: 17977545
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
6. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
Tani S; Matsumoto M; Nagao K; Hirayama A
J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
[TBL] [Abstract][Full Text] [Related]
7. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
8. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
9. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
[TBL] [Abstract][Full Text] [Related]
10. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Nguyen SV; Nakamura T; Uematsu M; Fujioka D; Watanabe K; Watanabe Y; Obata JE; Nakamura K; Kugiyama K
J Cardiol; 2017 Mar; 69(3):529-535. PubMed ID: 27256217
[TBL] [Abstract][Full Text] [Related]
11. High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome.
Nguyen SV; Nakamura T; Kugiyama K
Circ J; 2014; 78(10):2492-500. PubMed ID: 25168189
[TBL] [Abstract][Full Text] [Related]
12. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
13. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
[TBL] [Abstract][Full Text] [Related]
14. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients.
Ito M; Arishima T; Kudo T; Nishihara E; Ohye H; Kubota S; Fukata S; Amino N; Kuma K; Sasaki I; Hiraiwa T; Hanafusa T; Takamatsu J; Miyauchi A
J Clin Endocrinol Metab; 2007 Feb; 92(2):608-11. PubMed ID: 17148561
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus.
Fukushima H; Sugiyama S; Honda O; Koide S; Nakamura S; Sakamoto T; Yoshimura M; Ogawa H; Fujioka D; Kugiyama K
J Am Coll Cardiol; 2004 Jun; 43(12):2219-24. PubMed ID: 15193683
[TBL] [Abstract][Full Text] [Related]
16. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis.
Nakamura T; Obata JE; Takano H; Kawabata K; Sano K; Kobayashi T; Fujioka D; Saito Y; Yano T; Kugiyama K
Atherosclerosis; 2009 Jan; 202(1):234-40. PubMed ID: 18456269
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
18. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: a report from the CREDO-Kyoto registry cohort-2.
Izuhara M; Ono K; Shiomi H; Morimoto T; Furukawa Y; Nakagawa Y; Shizuta S; Tada T; Tazaki J; Horie T; Kuwabara Y; Baba O; Nishino T; Kita T; Kimura T;
Atherosclerosis; 2015 Oct; 242(2):632-8. PubMed ID: 26022139
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
